• Mashup Score: 0
    Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status - 2 year(s) ago

    The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Nivolumab + ipilimumab improved OS vs chemo with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial. @myESMO #ESMOImmuno21 #lcsm https://t.co/GLIe0IxDpv

  • Mashup Score: 0
    Frontline Nivolumab/Ipilimumab Improves OS in Advanced NSCLC, Irrespective of Mutational Status - 2 year(s) ago

    The dual immunotherapy combination comprised of nivolumab and ipilimumab improved overall survival vs chemotherapy in patients with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial.

    Source: OncLive
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncLive
      OncLive

      Nivolumab + ipilimumab improved OS vs chemo with advanced non–small cell lung cancer, irrespective of KRAS, TP53, or STK11 mutational status, according to data from exploratory analyses of part 1 of the CheckMate-227 trial. @myESMO #ESMOImmuno21 #lcsm https://t.co/2S7EtHea30 https://t.co/w1BVKijBa3

  • Mashup Score: 2
    ESMO Immuno-Oncology Congress | OncologyPRO - 2 year(s) ago

    OncologyPRO is the home of ESMO’s educational & scientific resources, with exclusive content for ESMO members such as ESMO’s Congresses webcasts,

    Source: oncologypro.esmo.org
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      Meeting resources from #ESMOImmuno21 now available online for you to access new insights and dive deeper into the latest discoveries in #immunooncology presented at the Congress 👉 https://t.co/jX1DolDpqt #MedTwitter #immunotherapy #cancerresearch https://t.co/AlbixFxva2

  • Mashup Score: 3
    Biomarkers for immunotherapy: where are we? - 2 year(s) ago

    For Andrew Furness, Royal Marsden NHS Foundation Trust, London, no single biomarker is likely to reflect the complexity of the tumour microenvironment

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: The future is in the hands of tools built on combinations of #biomarkers as no single one likely to reflect complexity of tumour microenvironment or account for tumour evolution Educational Session 10/12 at 14:30 https://t.co/xFqPdSfEb1 @ajsfurness #immunotherapy https://t.co/PLvky2970c

  • Mashup Score: 11
    How much is enough with immunotherapy? - 2 year(s) ago

    For Dr Jedd Wolchok, one of the biggest challenges in the field is knowing how and when to de-escalate immunotherapy

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Award 2020 lecture 'Checkpoint blockade therapy for #melanoma: Combinations to improve outcomes', Jedd D. Wolchok, ESMO #Immuno-Oncology 2020 Award winner 🗓️ 10/12, 12:35 CET Daily Reporter article 'How much is enough with #immunotherapy?': https://t.co/0fG7rsfRBI https://t.co/4cwvbyZ5n1

  • Mashup Score: 9
    Refining patient selection for atezolizumab in resected NSCLC - 2 year(s) ago

    An exploratory analysis of the IMpower010 trial confirms that there is a correlation between tumour-cell PD-L1 expression and disease-free survival

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Refining pts selection for atezolizumab in resected #NSCLC. Results from an exploratory analysis of the IMpower010 trial confirm a correlation between tumour-cell PD-L1 expression & disease-free survival https://t.co/1qWz7sOuCp @MartinReck2 #immunotherapy #lcsm https://t.co/WXveAGSYMl

  • Mashup Score: 6
    NSCLC, ctDNA changes after neoadjuvant therapy - 2 year(s) ago

    A study associates reductions in ctDNA with major pathologic response following neoadjuvant atezolizumab in resectable stage IB–IIIB NSCLC

    Source: Daily Reporter
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of M_Khettab
      M_Khettab

      RT @myESMO: #ESMOImmuno21: Can #ctDNA changes after neoadjuvant therapy inform management of early #NSCLC? 👉 https://t.co/OJZvNLoKI9 #immu…

    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Can #ctDNA changes after neoadjuvant therapy inform management of early #NSCLC? 👉 https://t.co/OJZvNLoKI9 #immunotherapy @HendriksLizza #lcsm https://t.co/O3FjbnoTvZ

  • Mashup Score: 0
    Defining patient groups for immunotherapy - 2 year(s) ago

    Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups

    Source: Daily Reporter
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of myESMO
      myESMO

      #ESMOImmuno21: Sub-group analyses of CheckMate 227 part 1 provide reassurance but no definite guidance regarding standard treatment for different patient sub-groups. https://t.co/5SpgQ8dxE3 #immunotherapy @BenjaminBesseMD #lcsm #nsclc https://t.co/zKmP2Us45A

Load More